Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.

How Is The Eosinophilic Asthma Market Expected To Grow In Terms Of Size?

The market size for eosinophilic asthma has witnessed a swift expansion in recent years. It is set to escalate from a value of $2.69 billion in 2024 to $3.16 billion in 2025, with a compound annual growth rate (CAGR) of 17.4%. Factors contributing to this growth during the historical period include an escalation in pollution levels, decreased immunity among the population, an upturn in eosinophilic asthma cases, increased prevalence of allergens and respiratory conditions, a surge in healthcare spending, as well as an enhancement in research and development activities.

The market size of eosinophilic asthma is predicted to witness a rapid expansion in the coming years, with a projected growth to $5.95 billion in 2029 at a compound annual growth rate of 17.1%. This upward trajectory in the forecast period can be linked to the rise in respiratory diseases, increased consciousness and diagnosis rates, broadening applications for monoclonal antibodies, amplified investments in healthcare infrastructure, and the growth of personalized medicine strategies. Noteworthy trends during the forecast period comprise the advent of targeted biologics, better diagnostic instruments, bespoke treatment approaches, advanced drug delivery systems, incorporation of digital health technologies, and widened clinical trials for innovative therapies.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21184&type=smp

Which Key Factors Are Fueling Growth In The Eosinophilic Asthma Market?

The upward trend in smoking habits is anticipated to spur the eosinophilic asthma market’s expansion. The term “smoking habits” refers to the habitual use of tobacco products, including the frequency, context, and duration, which are often shaped by psychological, social, and environmental influences. The proliferation of smoking habits can be attributed to factors such as elevated stress levels, aggressive advertising strategies by tobacco firms, lack of knowledge about health repercussions, and social approval of smoking in certain societies. Treatment for eosinophilic asthma, which diminishes airway inflammation and enhances lung function, may promote smoking cessation by addressing the respiratory problems that frequently compel individuals to persist with smoking. For example, the National Health Service, a UK governmental body, revealed in December 2023 that hospital admissions due to smoking had risen to around 408,700 in 2022–23 from 389,800 in 2021–22, marking a 4.8% surge. Consequently, the increased incidence of smoking propels the growth of the eosinophilic asthma market.

How Is The Eosinophilic Asthma Market Categorized Across Applications And Types?

The eosinophilic asthmamarket covered in this report is segmented –

1) By Disease: Severe Eoisnophilic Asthma; Mild To Moderate Eosinophilic Asthma

2) By Treatment: Biologics; Bronchodilators; Corticosteroids; Immunomodulators; Other Treatments

3) By End User: Hospitals; Clinics; Other End Users

Subsegments:

1) By Severe Eosinophilic Asthma: Refractory Eosinophilic Asthma; Late-Onset Eosinophilic Asthma

2) By Mild To Moderate Eosinophilic Asthma: Early-Onset Eosinophilic Asthma; Intermittent Eosinophilic Asthma

How Are Market Trends Influencing Competition In The Eosinophilic Asthma Market?

Major companies in the eosinophilic asthma market are working on novel drugs that target specific immune pathways to reduce inflammation and offer personalized treatment to improve patient outcomes. Monoclonal antibodies—lab-created molecules that mimic the immune system’s pathogen-fighting ability—are produced by merging antibody-producing cells with cancer cells, allowing large-scale production of identical antibodies. For instance, in August 2024, UK-based biopharmaceutical company AstraZeneca plc announced that its drug Fasenra received approval from China’s National Medical Products Administration for treating severe eosinophilic asthma. Designed for patients with elevated eosinophil levels, Fasenra is a monoclonal antibody that binds to the IL-5 receptor on eosinophils to reduce their presence in blood and tissues. The treatment includes an initial loading phase with injections every four weeks for the first three doses, followed by maintenance doses every eight weeks.

Which Firms Are Making The Biggest Impact In The Eosinophilic Asthma Market?

Major companies operating in the eosinophilic asthma market are Roche Holding AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Novartis AG, GSK plc, Amgen Inc., Viatris Inc., Teva Pharmaceutical Industries Limited, Boehringer Ingelheim GmbH, Regeneron Pharmaceuticals Inc., Chiesi Farmaceutici S.p.A.

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/eosinophilic-asthma-global-market-report

Which Region Holds The Greatest Opportunity For Eosinophilic Asthma Market Expansion?

North America was the largest region in the eosinophilic asthma market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the eosinophilic asthma market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=21184&type=smp

Browse Through More Reports Similar to the Global Eosinophilic Asthma Market 2025, By The Business Research Company

Anti Asthmatics And Copd Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/anti-asthmatics-and-copd-drugs-global-market-report

Asthma Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/asthma-drugs-global-market-report

Autoimmune Disease Diagnosis Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/autoimmune-disease-diagnosis-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model